An observational study in Morbid Obesity, Hypertension and Type 2 DM, sponsored by The Hospital of Vestfold. Active, not recruiting at 1 site in Norway. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-06-11.
Sponsored by The Hospital of Vestfold · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 51 studies in Obesity, Morbid with a site in Norway — 22 open to participants now, 26 under way, none of them phase 3. Obesity, Morbid · Norway.
Among the 51 studies in Obesity, Morbid with a site in Norway, this one is the 3rd largest by enrollment of the 30 observational ones that give a count, is one of 3 that started in 2008, is one of 30 observational ones, reaches primary completion later than 18 of the 25 other live ones, and was the 4th registered.
941 studies on the registry are indexed under Obesity, Morbid; 162 are open to participants now.
Browse Obesity, Morbid studies →22 of the 51 studies in Obesity, Morbid with a site in Norway are open now. Recruiting first, the newest first:
Oslo University Hospital · Sites in Norway
Ages 20–60
Norwegian University of Science and Technology · Sites in Norway
Ages 18–70
Norwegian University of Science and Technology · Sites in Norway
Ages 18–70
Norwegian University of Science and Technology · Sites in Norway
Ages 18–70
Norwegian University of Science and Technology · Sites in Norway
Ages 18–70
A study can be open while its sites in Norway have not opened yet or have stopped. Only those recruiting at a site in Norway →
Of the 109 Obesity, Morbid studies recruiting now, 21 (19%) set no upper age limit and 83 (76%) stop at 75 or younger; 8 take children under 18; 9 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
51 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 3 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 200 is above the median of 80 across 311 observational studies indexed under Obesity, Morbid.
Median enrollment 69 across the 21 interventional studies, 12 across the 30 observational. Of the 23 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 51 has an industry lead sponsor. The 10 most frequent:
The Hospital of Vestfold is the lead sponsor of 16 studies on the registry; 2 are open to participants now.
The Hospital of Vestfold has 3 studies filed under Obesity, Morbid — fewer than ten, so there is no comparison to draw.
6 of the studies in Obesity, Morbid with a site in Norway that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT00626964The Hospital of VestfoldPrevention of Coronary Heart Disease in Morbidly Obese Patients | 2026-12 |
| NCT02767505Göteborg UniversityBypass Equipoise Sleeve Trial (BEST) | 2026-12 |
| NCT03448783Norwegian University of Science and TechnologyBariatric Surgery and Pharmacokinetics of Apixaban | 2026-12 |
| NCT03440177Norwegian University of Science and TechnologyBariatric Surgery and Pharmacokinetics of Ramipril | 2026-12 |
| NCT03449485Norwegian University of Science and TechnologyBariatric Surgery and Pharmacokinetics of Chlorprothixene | 2026-12 |
Add all 6 to your calendar (.ics) → With an account.
Among the 51 studies in Obesity, Morbid with a site in Norway, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The changes in risks of developing coronary heart disease in patients with morbid obesity after different weight loss interventions have not been extensively studied. The primary objective of this study is to investigate whether an intensive lifestyle intervention program in a tertiary care clinic (Spesialsykehuset for Rehabilitering) is comparable with a 7-week low-energy-diet followed by bariatric surgery in decreasing the risk of cardiovascular disease in these patients.
Patients matching the eligibility criteria were divided into two groups (not randomized). One group underwent a 7 weeks Low-Energy-Diet before bariatric surgery, the other group participated in an intensive lifestyle intervention program for 3 months.
Data on arterial stiffness, body weight, body composition, blood pressure, blood samples, vital parameters are registered in the both groups at baseline, 7 weeks and after 1 year.
Morbidly Obese patients with BMI > 40, or BMI > 35 with comorbidity such as Hypertension, Obstructive Sleep Apnea, Weight Related Osteoarthrosis, Type 2 DM.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Morbid Obesity with BMI \>= 40 kg/m2 or BMI \>= 35 with Comorbidity
Procedure: Bariatric Surgery · Behavioral: Conservative Treatment:
Bariatric Surgery Treatment: Duodenal Switch, Gastric Sleeve or Gastric bypass.
Intensive Lifestyle Intervention Program
Also known as: Conservative
Arterial stiffness
Pulse wave velocity and augmentation index
Time frame: 7 weeks and 1 year
Cardiovascular risk factors
Several biomarkers will be examined
Time frame: 7 weeks and 1 year
Plan to share: No
The record gives a start of Feb 2008, a primary completion of Dec 2026 and a completion of Dec 2026. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The Hospital of Vestfold